{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T11:11:18Z","timestamp":1773486678926,"version":"3.50.1"},"reference-count":88,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T00:00:00Z","timestamp":1692230400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Immunotherapy as a cancer treatment modality has undergone recent widespread proliferation across all cancer types, especially amongst patients with solid tumors. However, the longest tenured immunotherapy approach to cancer is allogeneic stem cell transplantation (allo-SCT) for two hematologic malignancies: acute myeloid and acute lymphoid leukemia (AML and ALL, respectively). While allo-SCT remains a standard of care for eligible patients, recent advances\/applications of monoclonal antibodies, immune checkpoint inhibitors, bispecific T-cell engagers (BiTEs), and CAR T-cell therapy are changing the treatment landscape for these acute leukemias by either direct to tumor immune targeting or through decreased toxicities that expand patient eligibility. Pre-clinical data and clinical trials have shown promising results for novel immunotherapies in acute leukemia, and multiple ongoing trials are investigating these novel approaches. While there have been promising results with these approaches, particularly in the relapsed\/refractory setting, there remain challenges in optimizing the use of these therapies, such as managing cytokine release syndrome and other immune-related toxicities. Immunotherapy is a rapidly evolving field in the treatment of acute leukemia and has the potential to significantly impact the management of both AML and ALL. This review highlights the history of immunotherapy in the treatment of acute leukemias, the evolution of immunotherapy into more targeted approaches, the potential benefits and limitations of different immune targeting approaches, and ongoing research and development in the field.<\/jats:p>","DOI":"10.3390\/cancers15164137","type":"journal-article","created":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T10:42:29Z","timestamp":1692268949000},"page":"4137","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Immunotherapy in Acute Leukemias: Past Success Paves the Way for Future Progress"],"prefix":"10.3390","volume":"15","author":[{"given":"Adel","family":"Chergui","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI 02903, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4877-6863","authenticated-orcid":false,"given":"John L.","family":"Reagan","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI 02903, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,8,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00000658-189112000-00015","article-title":"Contribution to the Knowledge of Sarcoma","volume":"14","author":"Coley","year":"1891","journal-title":"Ann. Surg."},{"key":"ref_2","first-page":"154","article-title":"The Toxins of William B. Coley and the Treatment of Bone and Soft-Tissue Sarcomas","volume":"26","author":"McCarthy","year":"2006","journal-title":"Iowa Orthop. J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1056\/NEJM195709122571102","article-title":"Intravenous Infusion of Bone Marrow in Patients Receiving Radiation and Chemotherapy","volume":"257","author":"Thomas","year":"1957","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1056\/NEJM197406202902501","article-title":"Bone-Marrow Transplantation for Hematologic Neoplasia in 16 Patients with Identical Twins","volume":"290","author":"Fefer","year":"1974","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1056\/NEJM197909133011109","article-title":"Marrow Transplantation for Acute Nonlymphoblastic Leukemia in First Remission","volume":"301","author":"Thomas","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"ref_6","first-page":"1525","article-title":"Adoptive Immunotherapy of Acute Leukemia: Experimental and Clinical Results","volume":"25","author":"Mathe","year":"1965","journal-title":"Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1056\/NEJM197905103001902","article-title":"Antileukemic Effect of Graft-versus-Host Disease in Human Recipients of Allogeneic-Marrow Grafts","volume":"300","author":"Weiden","year":"1979","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJM198106183042507","article-title":"Antileukemic Effect of Chronic Graft-versus-Host Disease: Contribution to Improved Survival after Allogeneic Marrow Transplantation","volume":"304","author":"Weiden","year":"1981","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.3324\/haematol.2019.245688","article-title":"History of Hematopoietic Cell Transplantation: Challenges and Progress","volume":"105","author":"Granot","year":"2020","journal-title":"Haematologica"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","article-title":"Graft-Versus-Leukemia Reactions After Bone Marrow Transplantation","volume":"75","author":"Horowitz","year":"1990","journal-title":"Blood"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1038\/leu.2014.145","article-title":"Sensitivity of Hematological Malignancies to Graft-versus-Host Effects: An EBMT Megafile Analysis","volume":"28","author":"Stern","year":"2014","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.bbmt.2019.10.003","article-title":"Ex Vivo T Cell-Depleted Hematopoietic Stem Cell Transplantation for Adult Patients with Acute Myeloid Leukemia in First and Second Remission: Long-Term Disease-Free Survival with a Significantly Reduced Risk of Graft-versus-Host Disease","volume":"26","author":"Montoro","year":"2020","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1182\/bloodadvances.2018027003","article-title":"The Impact of the Graft-versus-Leukemia Effect on Survival in Acute Lymphoblastic Leukemia","volume":"3","author":"Yeshurun","year":"2019","journal-title":"Blood Adv."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1182\/blood-2017-02-768762","article-title":"AML-Specific Cytotoxic Antibodies in Patients with Durable Graft-versus-Leukemia Responses","volume":"131","author":"Gillissen","year":"2018","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic Cell Transplantation (HCT)-Specific Comorbidity Index: A New Tool for Risk Assessment before Allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41409-022-01833-0","article-title":"A High Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) Does Not Impair Outcomes after Non-Myeloablative Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients 60 Years or Older","volume":"58","author":"Backhaus","year":"2023","journal-title":"Bone Marrow Transpl."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1056\/NEJMoa0811036","article-title":"Loss of Mismatched HLA in Leukemia after Stem-Cell Transplantation","volume":"361","author":"Vago","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa1808777","article-title":"Immune Escape of Relapsed AML Cells after Allogeneic Transplantation","volume":"379","author":"Christopher","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1182\/blood.2022015522","article-title":"Immune Landscape after Allo-HSCT: TIGIT- and CD161-Expressing CD4 T Cells Are Associated with Subsequent Leukemia Relapse","volume":"140","author":"Gournay","year":"2022","journal-title":"Blood"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/cncr.31896","article-title":"The Distribution of T-Cell Subsets and the Expression of Immune Checkpoint Receptors and Ligands in Patients with Newly Diagnosed and Relapsed Acute Myeloid Leukemia","volume":"125","author":"Williams","year":"2019","journal-title":"Cancer"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune Signature Drives Leukemia Escape and Relapse after Hematopoietic Cell Transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/j.bbmt.2013.09.011","article-title":"Outcome and Prognostic Factors for Patients Who Relapse After Allogeneic Stem Cell Transplantation","volume":"19","author":"Thanarajasingam","year":"2013","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for Patients with Relapse after Allogeneic Transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41409-019-0498-0","article-title":"The Role of Checkpoint Blockade after Allogeneic Stem Cell Transplantation in Diseases Other than Hodgkin\u2019s Lymphoma","volume":"54","author":"Holderried","year":"2019","journal-title":"Bone Marrow Transpl."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1182\/blood.2019004710","article-title":"A Multicenter Phase 1 Study of Nivolumab for Relapsed Hematologic Malignancies after Allogeneic Transplantation","volume":"135","author":"Davids","year":"2020","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1182\/bloodadvances.2022008403","article-title":"Pembrolizumab for the Treatment of Disease Relapse after Allogeneic Hematopoietic Stem Cell Transplantation","volume":"7","author":"Godfrey","year":"2023","journal-title":"Blood Adv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.bbmt.2020.01.021","article-title":"Unexpected Toxicities When Nivolumab Was Given as Maintenance Therapy Following Allogeneic Stem Cell Transplantation","volume":"26","author":"Wang","year":"2020","journal-title":"Biol. Blood Marrow Transpl."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in Myelodysplastic Syndromes Is Enhanced by Treatment with Hypomethylating Agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-142824","article-title":"Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed\/Refractory (R\/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response","volume":"136","author":"Daver","year":"2020","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed\/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e003392","DOI":"10.1136\/jitc-2021-003392","article-title":"Pembrolizumab and Decitabine for Refractory or Relapsed Acute Myeloid Leukemia","volume":"10","author":"Goswami","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1182\/bloodadvances.2021006138","article-title":"A Randomized Phase 2 Trial of Azacitidine with or without Durvalumab as First-Line Therapy for Older Patients with AML","volume":"6","author":"Zeidan","year":"2022","journal-title":"Blood Adv."},{"key":"ref_33","first-page":"S168","article-title":"Sabatolimab plus Hypomethylating Agents (Hmas) in Patients (Pts) with High-\/Very High-Risk Myelodysplastic Syndrome (Hr\/Vhr-Mds) and Acute Myeloid Leukemia (Aml): Subgroup Analysis of a Phase 1 Study","volume":"324576","author":"Wei","year":"2021","journal-title":"Eur. Hematol. Assoc. EHA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e2116427118","DOI":"10.1073\/pnas.2116427118","article-title":"Immunosuppression and Outcomes in Adult Patients with de Novo Acute Myeloid Leukemia with Normal Karyotypes","volume":"118","author":"Ferraro","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/sj.leu.2403391","article-title":"Cytosine Arabinoside Induces Costimulatory Molecule Expression in Acute Myeloid Leukemia Cells","volume":"18","author":"Vereecque","year":"2004","journal-title":"Leukemia"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e480","DOI":"10.1016\/S2352-3026(19)30114-0","article-title":"Idarubicin, Cytarabine, and Nivolumab in Patients with Newly Diagnosed Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome: A Single-Arm, Phase 2 Study","volume":"6","author":"Ravandi","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1158\/2643-3230.BCD-21-0070","article-title":"Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed\/Refractory Acute Myeloid Leukemia","volume":"2","author":"Zeidner","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.coi.2012.01.010","article-title":"The CD47\u2013SIRP\u03b1 Pathway in Cancer Immune Evasion and Potential Therapeutic Implications","volume":"24","author":"Chao","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Liu, J., Wang, L., Zhao, F., Tseng, S., Narayanan, C., Shura, L., Willingham, S., Howard, M., Prohaska, S., and Volkmer, J. (2015). Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0137345"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2022-170188","article-title":"Phase I\/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (Pts) with Newly Diagnosed (ND) Older\/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed\/Refractory (R\/R) AML","volume":"140","author":"Daver","year":"2022","journal-title":"Blood"},{"key":"ref_42","unstructured":"Gilead Sciences (2023, May 25). A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab Versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Previously Untreated Patients with Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy, Available online: https:\/\/www.clinicaltrials.gov."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1182\/blood.2020008850","article-title":"ALL in Escape Room","volume":"137","author":"Boissel","year":"2021","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1038\/s41375-020-0793-1","article-title":"Leukemia-Induced Dysfunctional TIM-3+CD4+ Bone Marrow T Cells Increase Risk of Relapse in Pediatric B-Precursor ALL Patients","volume":"34","author":"Blaeschke","year":"2020","journal-title":"Leukemia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1038\/s41375-018-0360-1","article-title":"Immune Cell Constitution in Bone Marrow Microenvironment Predicts Outcome in Adult ALL","volume":"33","author":"Hohtari","year":"2019","journal-title":"Leukemia"},{"key":"ref_46","first-page":"335","article-title":"Combining Nilotinib and PD-L1 Blockade Reverses CD4+ T-Cell Dysfunction and Prevents Relapse in Acute B-Cell Leukemia","volume":"140","author":"Tracy","year":"2022","journal-title":"Blood"},{"key":"ref_47","unstructured":"National Cancer Institute (NCI) (2023, May 25). A Phase 1 Study of Blinatumomab in Combination with Checkpoint Inhibitor(s) of PD-1 (Nivolumab) or Both PD-1 (Nivolumab) and CTLA-4 (Ipilimumab) in Patients with Poor-Risk, Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia, Available online: https:\/\/www.clinicaltrials.gov."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in de Novo Philadelphia Chromosome-Negative Precursor B-Lineage Acute Lymphoblastic Leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1056\/NEJMoa1605085","article-title":"Rituximab in B-Lineage Adult Acute Lymphoblastic Leukemia","volume":"375","author":"Maury","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for Minimal Residual Disease in Adults with B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"131","author":"Dombret","year":"2018","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","article-title":"Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults","volume":"383","author":"Bassan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukaemia: Phase 2 Results of the Single-Arm, Open-Label, Multicentre ZUMA-3 Study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients with Relapsed Low-Grade Non-Hodgkin\u2019s Lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1007\/s12325-017-0612-x","article-title":"Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience","volume":"34","author":"Salles","year":"2017","journal-title":"Adv. Ther."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"324","DOI":"10.3324\/haematol.2009.010306","article-title":"Adverse Prognostic Significance of CD20 Expression in Adults with Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"95","author":"Maury","year":"2010","journal-title":"Haematologica"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"6330","DOI":"10.1182\/blood-2008-04-151860","article-title":"Prognostic Significance of CD20 Expression in Adults with de Novo Precursor B-Lineage Acute Lymphoblastic Leukemia","volume":"113","author":"Thomas","year":"2009","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2017-07-794214","article-title":"Preclinical Efficacy of Daratumumab in T-Cell Acute Lymphoblastic Leukemia","volume":"131","author":"Bride","year":"2018","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.3324\/haematol.2018.192757","article-title":"CD38 as a Therapeutic Target for Adult Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia","volume":"104","author":"Naik","year":"2019","journal-title":"Haematologica"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41375-019-0548-z","article-title":"Daratumumab for Eradication of Minimal Residual Disease in High-Risk Advanced Relapse of T-Cell\/CD19\/CD22-Negative Acute Lymphoblastic Leukemia","volume":"34","author":"Ofran","year":"2020","journal-title":"Leukemia"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3324\/haematol.2021.279851","article-title":"Daratumumab with or without Chemotherapy in Relapsed and Refractory Acute Lymphoblastic Leukemia. A Retrospective Observational Campus ALL Study","volume":"107","author":"Cerrano","year":"2022","journal-title":"Haematologica"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"10001","DOI":"10.1200\/JCO.2022.40.16_suppl.10001","article-title":"Efficacy and Safety of Daratumumab (DARA) in Pediatric and Young Adult Patients (Pts) with Relapsed\/Refractory T-Cell Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL): Results from the Phase 2 DELPHINUS Study","volume":"40","author":"Hogan","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood.2022016774","article-title":"Please Eat Me! Targeting CD47 and CD38 in T-ALL","volume":"140","author":"Diorio","year":"2022","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jama.2021.0669","article-title":"Effect of Postreinduction Therapy Consolidation with Blinatumomab vs. Chemotherapy on Disease-Free Survival in Children, Adolescents, and Young Adults With First Relapse of B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"325","author":"Brown","year":"2021","journal-title":"JAMA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2021.0987","article-title":"Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children with High-Risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial","volume":"325","author":"Locatelli","year":"2021","journal-title":"JAMA"},{"key":"ref_68","first-page":"e566","article-title":"Updated Results of the GIMEMA LAL2116 D-ALBA Trial for Newly Diagnosed Adults with Ph+ ALL","volume":"5","author":"Chiaretti","year":"2021","journal-title":"HemaSphere"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jamaoncol.2022.2398","article-title":"Treatment of Adults with Philadelphia Chromosome\u2013Positive Acute Lymphoblastic Leukemia\u2014From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens: A Review","volume":"8","author":"Jabbour","year":"2022","journal-title":"JAMA Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"7508","DOI":"10.1200\/JCO.2020.38.15_suppl.7508","article-title":"Updated Results from Phase I Dose-Escalation Study of AMG 330, a Bispecific T-Cell Engager Molecule, in Patients with Relapsed\/Refractory Acute Myeloid Leukemia (R\/R AML)","volume":"38","author":"Ravandi","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1182\/blood-2019-127977","article-title":"Preliminary Results from a Phase 1 First-in-Human Study of AMG 673, a Novel Half-Life Extended (HLE) Anti-CD33\/CD3 BiTE\u00ae (Bispecific T-Cell Engager) in Patients with Relapsed\/Refractory (R\/R) Acute Myeloid Leukemia (AML)","volume":"134","author":"Subklewe","year":"2019","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-134746","article-title":"Complete Responses in Relapsed\/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study","volume":"136","author":"Ravandi","year":"2020","journal-title":"Blood"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1182\/blood.2020007732","article-title":"Flotetuzumab as Salvage Immunotherapy for Refractory Acute Myeloid Leukemia","volume":"137","author":"Uy","year":"2021","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-136398","article-title":"GTB-3550 TriKETM for the Treatment of High-Risk Myelodysplastic Syndromes (MDS) and Refractory\/Relapsed Acute Myeloid Leukemia (AML) Safely Drives Natural Killer (NK) Cell Proliferation at Initial Dose Cohorts","volume":"136","author":"Warlick","year":"2020","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-World Evidence of Tisagenlecleucel for Pediatric Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13045-022-01379-0","article-title":"Two-Year Follow-up of KTE-X19 in Patients with Relapsed or Refractory Adult B-Cell Acute Lymphoblastic Leukemia in ZUMA-3 and Its Contextualization with SCHOLAR-3, an External Historical Control Study","volume":"15","author":"Shah","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41417-023-00593-3","article-title":"Long-Term Response to Autologous Anti-CD19 Chimeric Antigen Receptor T Cells in Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis","volume":"30","author":"Elsallab","year":"2023","journal-title":"Cancer Gene Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","article-title":"UCART19, a First-in-Class Allogeneic Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia (CALM): A Phase 1, Dose-Escalation Trial","volume":"9","author":"Benjamin","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-Edited, Donor-Derived Allogeneic Anti-CD19 Chimeric Antigen Receptor T Cells in Paediatric and Adult B-Cell Acute Lymphoblastic Leukaemia: Results of Two Phase 1 Studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/s41409-020-01134-4","article-title":"Taming the Beast: CRS and ICANS after CAR T-Cell Therapy for ALL","volume":"56","author":"Sheth","year":"2021","journal-title":"Bone Marrow Transpl."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1200\/JCO.21.00917","article-title":"Durable Responses and Low Toxicity After Fast Off-Rate CD19 Chimeric Antigen Receptor-T Therapy in Adults with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia","volume":"39","author":"Roddie","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"7000","DOI":"10.1200\/JCO.2023.41.16_suppl.7000","article-title":"Safety and Efficacy of Obecabtagene Autoleucel (Obe-Cel, AUTO1), a Fast-off Rate CD19 CAR, in Relapsed\/Refractory Adult B-Cell Acute Lymphoblastic Leukemia (r\/r B-ALL): Top Line Results of the Pivotal FELIX Study","volume":"41","author":"Roddie","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"102479","DOI":"10.1016\/j.ctrv.2022.102479","article-title":"Toxicities Following CAR-T Therapy for Hematological Malignancies","volume":"111","author":"Hernani","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","article-title":"T-Cell-Based Immunotherapy of Acute Myeloid Leukemia: Current Concepts and Future Developments","volume":"35","author":"Daver","year":"2021","journal-title":"Leukemia"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V94.1.333.413a31_333_339","article-title":"Role of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation","volume":"94","author":"Ruggeri","year":"1999","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful Adoptive Transfer and in Vivo Expansion of Human Haploidentical NK Cells in Patients with Cancer","volume":"105","author":"Miller","year":"2005","journal-title":"Blood"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","article-title":"Exploring the NK Cell Platform for Cancer Immunotherapy","volume":"18","author":"Myers","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/16\/4137\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:35:27Z","timestamp":1760128527000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/16\/4137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,17]]},"references-count":88,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["cancers15164137"],"URL":"https:\/\/doi.org\/10.3390\/cancers15164137","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,17]]}}}